secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2026-08-26T10:14:58+00:00
Accession:  0001651308-26-000025
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeOne Medicines discloses H1 2026 R&D spend of $1.15B, up 14.6% YoY
-------------------------------------------------------------------

- Total R&D expense $1,153.5M in H1 2026 vs $1,006.8M in H1 2025, up 14.6% YoY.
- BRUKINSA R&D fell 33% to $42.7M from $63.0M; TEVIMRA down to $37.1M from $40.3M.
- BEQALZI (sonrotoclax) R&D $74.0M, down 21%; BGB-43395 CDK4 inhibitor surged to $22.7M vs $9.9M.
- Early-stage spend jumped: BGB-58067 $11.1M vs $1.9M, BG-C9074 $8.2M vs $2.4M, tacabrutideg $44.3M vs $26.9M.
- External R&D $435.1M vs $400.3M; internal R&D $718.4M vs $606.5M a year ago.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130826000025/0001651308-26-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130826000025/bgne-20260826.htm
  HTML page:      https://secwatch.observer/filing/0001651308-26-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer